PlaqueTec is a company that profiles the underlying biology of coronary artery disease and builds cohorts to endotype disease for the first time.

PlaqueTec

PlaqueTec is pursuing a better understanding of the biological mechanisms of coronary artery disease (CAD) to advance the development of precision medicine.

CAD, where atherosclerotic plaque build-up narrows or blocks the arteries that supply blood to the heart, is a leading cause of death globally. Current treatment approaches are one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression.

A more detailed understanding of patient endotypes will support drug development by identifying new targets in specific patient groups, reducing clinical trial sizes and costs, and increasing success rates, ultimately improving outcomes for patients.

PlaqueTec Ltd.

We're pleased to share that we have been shortlisted for this year's Business Weekly newspaper Awards!
 
These nominations reflect the milestones we've reached over the past twelve months with our BIOPATTERN trial and ongoing collaborations to drive our mission in the fight against coronary artery disease.
 
We're looking forward to ceremony later this year - congratulations to all the finalists!

Find out more here: https://rb.gy/u011m4
 
#Awards #Cambridge #LifeSciences #Innovation

Our team are at the BioBabraham Symposium today.
 
The event will showcase the innovation and breadth of research across Babraham Research Campus, with a series of campus spotlights taking place throughout the day. Our General Manager, Simon Williams, will be giving a talk in the afternoon, discussing our exciting technology and clinical trial.
 
If you're attending the event and are interested to find out more, feel free to come along and listen to Simon's talk.
 
#PrecisionMedicine #CoronaryArteryDisease #Cardiology #ClinicalTrial

PlaqueTec, a Cambridge company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has secured $8 million equity financing, led by Lord Moynihan of Chelsea alongside the Future Fund, with support from existing investors. https://lnkd.in/eUWaZuRN

The funding will be used to support PlaqueTec Ltd.’s ongoing BIOPATTERN trial, designed to improve understanding of CAD pathobiology and how it varies between individuals, and to build BIOCARTA® – its novel biomarker discovery tool.

BIOCARTA is a bioinformatics discovery platform that interrogates data and groups patients with CAD into endotypes with defined signatures of the disease. It correlates in vivo biomarkers localising at the disease site with plaque imaging, genomic analysis, blood biochemistry and clinical and demographic phenotypes to further enhance a unique understanding of disease. 

PlaqueTec, based in the Maia Building at Babraham Research Campus is using BIOCARTA to identify biomarkers to accurately assess patients and therefore inform more targeted therapeutic interventions, transforming patient care.

Martin Stapleton, Chairman, PlaqueTec, said: “CAD is a leading cause of death worldwide and represents an area with significant unmet medical need. 

“The continued support from our existing investors and additional funding from the Future Fund reinforces the potential of our technology and BIOCARTA database, and brings us closer to achieving our vision of opening a new frontier of precision medicine for millions of patients with CAD worldwide.”

PlaqueTec Ltd. have announced that it has secured $8 million equity financing, led by Lord Moynihan of Chelsea alongside the Future Fund, with support from existing investors.

#Pharma

We've arrived at BIO in San Diego and are looking forward to catching up with colleagues and partners from across the biotech landscape.
 
This year's convention boasts a full programme of speaker sessions and presentations from a range of global industry leaders.
 
Don't miss our session with General Manager Simon Williams today at 1:45pm (PDT).
 
Find out more here: https://rb.gy/k8hlxt
 
#BIO2024 #Biotech #Partnering #Medtech #PrecisionMedicine

Our team had a fantastic few days at BIO last week!
 
It was great to connect with potential partners and to hear from individuals from all corners of the biotech industry on the latest developments and exciting innovations and discoveries in research.
 
If you didn't get a chance to meet with us last week and are interested to learn more about how we're pioneering a precision medicine approach for millions of patients with coronary artery disease worldwide, please get in touch: https://rb.gy/q20ui3
 
#BIO2024 #Partnering #Networking #PrecisionMedicine

Metric
Company Name	PlaqueTec
Symbol
MSH ID	COM:PLAQUETEC
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	GB
Stage
Employee Count	5
Website	plaquetec.com
LinkedIn	plaquetec-ltd
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

PLAQ

COM:PLAQUETEC

PlaqueTec

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue